Medtronic (MDT) Down 11.5% Since Last Earnings Report: Can It Rebound?

Core Viewpoint - Medtronic's recent earnings report shows mixed results, with a slight decline in adjusted earnings per share and a notable increase in revenues, but the stock has underperformed the S&P 500, raising questions about its future performance [1][2]. Financial Performance - Medtronic reported Q3 fiscal 2026 adjusted earnings per share of $1.36, a decrease of 2.2% year-over-year, but it exceeded the Zacks Consensus Estimate by 2.07% [3]. - The company's worldwide revenues for the quarter reached $9.02 billion, reflecting an 8.7% year-over-year increase on a reported basis and 6% organically, surpassing the Zacks Consensus Estimate by 1.35% [4]. Segmental Analysis - Revenues from the Cardiovascular segment increased 10.6% organically to $3.46 billion, with Cardiac Rhythm & Heart Failure sales rising 17% year-over-year to $1.86 billion [5][6]. - The Medical Surgical segment reported worldwide sales of $2.17 billion, up 2.7% year-over-year organically, with Acute Care & Monitoring revenues increasing by 7% to $519 million [7]. - Neuroscience revenues totaled $2.56 billion, up 2.5% year-over-year organically, while revenues in the Diabetes group rose 8.3% organically to $796 million [8]. Margin Performance - The gross margin contracted by 265 basis points to 63.8%, attributed to a 17.3% increase in the cost of products sold [9]. - Research and development expenses rose by 7% year-over-year to $722 million, and selling, general, and administrative expenses increased by 8.8% to $2.96 billion [9]. Future Outlook - For fiscal 2026, Medtronic projects organic revenue growth of 5.5%, with the Zacks Consensus Estimate for worldwide revenues at $36.04 billion [10]. - The expected full-year adjusted earnings per share range is $5.62-$5.66, with the Zacks Consensus Estimate at $5.64 [11]. Estimate Trends - Recent estimates for Medtronic have trended downward, indicating a potential shift in investor sentiment [12][14]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of an in-line return in the coming months [14]. Industry Comparison - Medtronic operates within the Zacks Medical - Products industry, where competitor Phibro Animal Health has seen a 2.3% gain over the past month, reporting revenues of $373.9 million, a year-over-year increase of 20.9% [15]. - Phibro's expected earnings for the current quarter are $0.72 per share, reflecting a 14.3% increase from the previous year, with a Zacks Rank 1 (Strong Buy) [16].